
Market Cap: $80M
1Q26 Cash: $8.8M
2026E Revenue: $41.6M
EV/2026E Revenue: ~1.7x
CG Rating
Price Target
Upside
20%+ year-over-year growth driven by VA, prescription, and fast-scaling consumer channels.
An 85–87% gross margin business positioned to scale toward EBITDA breakeven as revenue expands.
FDA-cleared migraine and fibromyalgia therapies with growing wellness and military applications.
ECOR: Price Performance